| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Gene Therapies | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Gene Therapies | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Gene Therapies | Oncology |
Recent Updates
Recently added Catalysts
Caribou Biosciences, Inc.$1.93
+0.02 (+0.99%)
D 26Pipeline Score Overvalued Biotech · Commercial
Market Cap
208.28 M
EPS
-1.42
P/E Ratio
-
Value Trade
4.48 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
2.40 M
R&D Expenses
20.61 M
Operating CF
-26.98 M
Total Assets
149.00 M
Total Liabilities
46.98 M
Equity
102.02 M
D/E Ratio
12,345
-1.41 %
Week
-8.3 %
1 Month
20 %
3 Month
20.69 %
6 Month
-88.1 %
5 Year
-88.1 %
All Time
Cash Data
Cash Position
117.63 M
Monthly Burn
8.99 M
Runway
11.2 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
3.48 M
52 Week Range
0.96 - 3.54
% held by Insiders
9.73 %
% held by Institutions
36.31 %
Enterprise Value
117.60 M
Total Shares
99.23 M
Short %
11.16 %
Float Shares
86.23 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Caribou Biosciences, Inc.
223Total events
3Upcoming
32Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 3
Event history 220
Jun 12, 2026
◆Oral Presentationvispa-celPresentation
EHA 2026 oral presentation of long-term vispa-cel data in 2L LBCL
relapsed or refractory B cell non-Hodgkin lymphomasource ↗
Jun 12, 2026
▲Full Resultsvispa-celClinical Data
Long-term efficacy and safety data from ANTLER phase 1 in 2L LBCL (data cutoff March 6, 2026)
second-line large B cell lymphomasource ↗
May 13, 2026
May 7, 2026
▲FDA Feedback Receivedvispa-celFDA Meeting
FDA alignment on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL
second-line large B cell lymphomasource ↗
Mar 31, 2026
▲RMATCB-011Designation
FDA granted RMAT designation to CB-011
relapsed or refractory multiple myelomasource ↗
Mar 10, 2026
Mar 5, 2026
Feb 7, 2026
▲Oral PresentationCB-011Presentation
Oral presentation at 2026 Tandem Meetings including clinical data disclosed in November 2025 and new supportive translational data
relapsed or refractory multiple myelomasource ↗
Feb 5, 2026
▲Poster Presentationvispacabtagene regedleucelPresentation
Poster presentation at 2026 Tandem Meetings including clinical data disclosed in November 2025 and new supportive translational data
relapsed or refractory B cell non-Hodgkin lymphomasource ↗
2026
◆Topline ReadoutCB-011Clinical Data
Initial dose expansion data and longer follow-up on dose escalation data expected
relapsed or refractory multiple myelomasource ↗
2026
◆Oral Presentationvispa-celPresentation
Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026
relapsed/refractory B cell non-Hodgkin lymphomasource ↗
Drug Pipeline Intelligence
D26
Pipeline Score $15M
Pipeline ValueOvervalued
Valuation Signal1
Drugs Scored0.2x
rNPV / MCap Top 27%
Micro Cap (rank 666 of 911)
Percentile RankCaribou Biosciences, Inc. faces pipeline headwinds (26/100), with $226M risk-adjusted pipeline value, led by CB-011 in Relapsed/Refractory Multiple Myeloma (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CB-011 Monoclonal antibody | Relapsed/Refractory Multiple Myeloma | Phase 1 | NCT05722418 | 27% | $226M | RECRUITING | 50 | STALLED | D (26) | Dec 1, 2027 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
vispa-cel | second-line large B cell lymphoma | Phase 1 | 2026-06-12 | overall response rate: 82%; complete response rate: 67%; median progression free survival: 17.1 months Read More | Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 -- Single dose of vispa-cel produced durable responses in 2L LBCL patients 82% ORR, 67% CR rate, and 17.1-month mPFS - Read More | |
vispa-cel | second-line large B cell lymphoma | Phase 1 | 2026-06-12 | overall response rate: 82%; complete response rate: 67%; median progression free survival: 17.1 months Read More | Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 -- Single dose of vispa-cel produced durable responses in 2L LBCL patients 82% ORR, 67% CR rate, and 17.1-month mPFS - Read More | |
vispa-cel | second-line large B cell lymphoma | Phase 1 | 2026-06-12 | overall response rate: 82%; complete response rate: 67%; median progression free survival: 17.1 months Read More | Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 -- Single dose of vispa-cel produced durable responses in 2L LBCL patients 82% ORR, 67% CR rate, and 17.1-month mPFS - Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CRBU
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CRBU Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CRBUCaribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 -- Single dose of vispa-cel produced durable responses in 2L LBCL patients 82% ORR, 67% CR rate, and 17.1-month mPFS -
Caribou Biosciences reported promising long-term data for vispa-cel, a CAR-T cell therapy for second-line large B cell lymphoma (LBCL), showing an 82% overall response rate and a 67% complete response rate. The therapy is designed to be an off-the-shelf solution for patients lacking curative treatment options. It holds promise due to its favorable safety profile and potential for outpatient administration. However, there are concerns following reports of serious adverse events, including deaths linked to the treatment.
Read more →CRBUCaribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update -- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longer follow up on vispa-cel p
Caribou Biosciences reported its first quarter 2026 financial results and outlined progress in its clinical programs. The company achieved alignment with the FDA on the ANTLER-3 trial design for vispa-cel, an allogeneic CAR-T cell therapy for patients with relapsed or refractory large B cell lymphoma. Ongoing trials for CB-011 and updates on its clinical data are also anticipated in 2026. Financially, Caribou reported stable licensing revenue but noted a decrease in R&D expenses compared to the previous year.
Read more →CRBU▲ +10.5%on this news
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy -- RMAT granted based on promising initial clinical data, incl
Caribou Biosciences has received RMAT designation from the FDA for its allogeneic anti-BCMA CAR-T cell therapy, CB-011, aimed at treating relapsed or refractory multiple myeloma. This designation is based on promising initial clinical data, showing a 92% overall response rate and a 75% complete response rate in early trial participants. The ongoing CaMMouflage phase 1 clinical trial continues to evaluate the safety and efficacy of CB-011, with expected data updates in 2026. The designation aims to facilitate faster regulatory review to address unmet medical needs in this patient population.
Read more →CRBU▼ -5%on this news
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Caribou Biosciences reported its financial results for Q4 and full year 2025, highlighting a year of strong execution with advancements in its CAR-T cell therapy programs. The company showed positive phase 1 data for its allogeneic vispa-cel in LBCL and initiated dose expansion for CB-011 targeting multiple myeloma. Despite an increased revenue of $11.2 million from licensing collaborations, Caribou also faced challenges with a GAAP net loss of $148.1 million and recorded impairment charges. Ongoing engagement with the FDA for trial designs is set to facilitate further developments in 2026.
Read more →CRBUCaribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update Vispa-cel (CB-010) ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safet
Caribou Biosciences reported positive financial results and significant clinical data for Vispa-cel and CB-011 in their third quarter 2025 update. The ANTLER phase 1 trial for Vispa-cel showed promising efficacy results, indicating potential as a leading allogeneic CAR-T therapy for large B-cell lymphoma. Similarly, CB-011 demonstrated strong responses in patients with relapsed or refractory multiple myeloma. The company is advancing both therapies while having enough financial resources to continue their development.
Read more →CRBUCaribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies Data demons
Caribou Biosciences announced favorable results from its ANTLER Phase 1 trial, indicating that its allogeneic CAR-T cell therapy, vispa-cel, shows comparable efficacy and durability to autologous CAR-T therapies in patients with relapsed or refractory large B cell lymphoma. With an overall response rate of 86% and a complete response rate of 63% in the optimized cohort, vispa-cel was also noted for its favorable safety profile, allowing for outpatient treatment. The company plans to move forward with regulatory discussions for a pivotal Phase 3 clinical trial to seek full approval.
Read more →CRBUCaribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update -- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $184 million in cash, cash e
Caribou Biosciences has released its financial results for Q2 2025, showcasing a strong cash position of $184 million, sustaining operations into 2027. The company is focused on its CAR-T cell programs, CB-010 and CB-011, with promising data disclosures expected in H2 2025. Despite increasing net losses and a decrease in licensing revenue, encouraging Phase 1 results from both clinical trials reinforce the potential of these therapies.
Read more →CRBUCaribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update -- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash
Caribou Biosciences reported its first-quarter 2025 financial results, revealing a net loss of $40 million and $212.5 million in cash reserves, projected to sustain operations until H2 2027. The company is focused on its lead clinical programs CB-010 and CB-011, both showing promising efficacy and aiming to release significant clinical dataset updates in the second half of 2025. Recent restructuring includes a workforce reduction and the discontinuation of non-core clinical trials, optimizing resources for its oncology therapies.
Read more →CRBUCaribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs -- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company's c
Caribou Biosciences announced a strategic prioritization of its oncology pipeline, focusing on clinical programs CB-010 and CB-011. This decision involves workforce and cost reductions to extend its cash runway to H2 2027. As part of this strategic shift, the company will disclose robust clinical datasets for its lead programs in H2 2025, reinforcing its commitment to addressing unmet needs in oncology. The changes also entail discontinuation of trials outside of its primary focus areas, which may impact its pipeline diversity.
Read more →CRBUCaribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update -- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r r MM Phase 1 clinical data expected in H1 2025 -- -- Advancin
Caribou Biosciences has reported its financial results for Q4 and full year 2024, highlighting its ongoing clinical developments. The company plans to disclose two clinical data sets related to its CAR-T cell therapies in the first half of 2025. Despite a decrease in licensing revenue due to the termination of a collaboration with AbbVie, Caribou maintains a strong cash position that will fund its operations through 2026. Encouraging early results from clinical trials suggest potential improvements in patient outcomes.
Read more →CRBU▼ -5.5%on this news
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 -- CB-010 GALLOP Phase 1 trial initiated in lupus -- -- CB-012 AMpLify Phase 1 trial in r
Caribou Biosciences has initiated the GALLOP Phase 1 trial to evaluate its CAR-T cell therapy CB-010 in patients with lupus nephritis and extrarenal lupus. The company reported strong progress across its allogeneic CAR-T programs and outlined its clinical data expectations for 2025. With FDA Fast Track designations and a $281 million cash runway, Caribou is well-positioned to advance its key programs, including CB-010. The CEO expressed optimism about the potential impact of their therapies in the treatment landscape.
Read more →CRBU▲ +5.7%on this news· ran to +18% by day 3
Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer
Caribou Biosciences has appointed Sri Ryali as Chief Financial Officer, effective immediately. With over 20 years of finance and commercial experience in the biopharmaceutical industry, Mr. Ryali will oversee corporate finance, investor relations, and communications. His previous roles include CFO at Codexis and Eiger BioPharmaceuticals, bringing valuable expertise as Caribou plans to advance its clinical-stage programs in 2025 amidst ongoing developments in CRISPR genome editing technologies.
Read more →CRBU▲ +7.4%on this news
Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases multiple clinical data reports
Caribou Biosciences reported its financial results for Q3 2024, highlighting progress across four clinical-stage programs aimed at treating hematologic malignancies and autoimmune diseases. Notably, the company's CB-010 therapy received Fast Track designation by the FDA for systemic lupus erythematosus. They are currently enrolling patients in multiple trials, including the CB-011 CaMMouflage and CB-010 ANTLER trials, with data reporting anticipated in 2025. Despite a decrease in licensing revenue and increased R&D expenditure, the company retains a stable financial position with $281 million in available funds.
Read more →CRBUCaribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer --Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell ther
Caribou Biosciences has appointed Dr. Tina Albertson as its new Chief Medical Officer. Dr. Albertson, who has 15 years of experience in clinical drug development, will lead the clinical, regulatory, and medical affairs for Caribou's ongoing clinical programs. Her previous roles include leadership positions at Lyell Immunopharma and Juno Therapeutics, where she successfully drove the development of CAR-T therapies. Dr. Albertson's expertise is anticipated to be valuable as Caribou advances its allogeneic CAR-T cell therapies for hematologic malignancies and autoimmune diseases.
Read more →CRBUCaribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases clinical data reports planned
Caribou Biosciences has reported its financial results for Q2 2024, highlighting progress in four clinical programs targeting hematologic malignancies and autoimmune diseases. The company has extended its cash runway into the second half of 2026, bolstered by reducing workforce and costs. Promising data from the CB-010 Phase 1 trial suggests potential competitiveness against existing CAR-T therapies. However, a decrease in licensing revenue and job cuts raise concerns regarding future operational stability.
Read more →CRBU▼ -25.5%on this news
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- CB-010 allogeneic CAR-T cell
Caribou Biosciences presented encouraging data from its ANTLER Phase 1 trial for CB-010, an allogeneic CAR-T cell therapy, at the ASCO Annual Meeting. The therapy demonstrated a median progression-free survival of 14.4 months in patients with a partial HLA matching of four alleles, showing efficacy potential similar to that of standard autologous therapies. The company plans to enroll 20 additional patients to confirm these findings, with a pivotal Phase 3 trial anticipated to begin in late 2025, contingent upon further validating improved patient outcomes.
Read more →CRBUCaribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update -- Advancing CB-010 ANTLER Phase 1 trial for 2L LBCL initial dose expansion data to be presented at the 2024 American Society
Caribou Biosciences has released its financial results for the first quarter of 2024 while updating its business progress. The company is advancing its clinical trials, notably for the allogeneic CAR-T therapy CB-010, with data set to be presented at the 2024 ASCO Annual Meeting. Additionally, it has received FDA clearance for an IND in the treatment of lupus nephritis and is planning to initiate the corresponding clinical trial by the end of the year. Despite having sufficient funds to support operations until 2026, Caribou also reported an increased net loss and decreased revenue from collaborations compared to the prior year.
Read more →CRBUCaribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus -- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus GALLOP Phase 1 clinical trial
Caribou Biosciences has announced FDA clearance of its IND application for CB-010, an allogeneic CAR-T cell therapy targeting lupus nephritis and extrarenal lupus. The company is set to initiate the GALLOP Phase 1 clinical trial by the end of 2024, expanding the therapy's development beyond its initial focus on non-Hodgkin lymphoma. The GALLOP trial will evaluate the safety and initial clinical activity of CB-010 in affected patients and aims to offer new therapeutic options for lupus, a condition characterized by severe autoimmune responses.
Read more →CRBUCaribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update -- 30 th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion initial dose expansion data and RP2D to be
Caribou Biosciences reported its financial results for Q4 and full year 2023, highlighting significant progress in its clinical trials. Notably, the company has dosed the 30th patient in the CB-010 ANTLER Phase 1 trial and initiated dosing for the first patient in the CB-012 AMpLify trial. The company has a strong cash position, with $372.4 million anticipated to support operations until early 2026. Initial data from CB-010's dose expansion is expected to be released in Q2 2024, amid ongoing efforts in three key CAR-T cell therapy programs.
Read more →CRBU▲ +19.1%on this news
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024 -- Tim Kelly to lead Caribou's technical operations strategy and execution -- -- CB-010 ANTLE
Caribou Biosciences has appointed Tim Kelly as its Chief Technology Officer, a strategic move as the company prepares to advance its clinical pipeline. The appointment is highlighted by multiple clinical catalysts expected in 2024, including significant trials for its CAR-T cell therapies. Notably, the company plans to initiate a pivotal Phase 3 trial for CB-010 in second-line large B cell lymphoma by the end of 2024. With a strong leadership team and promising data from ongoing trials, Caribou aims to leverage its innovation in genome editing to address critical medical needs.
Read more →CRBUCaribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024 -- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a
Caribou Biosciences announced a regulatory update regarding its lead therapy, CB-010, following discussions with the FDA. The company gained FDA approval for a pivotal Phase 3 trial in second-line relapsed or refractory large B cell lymphoma (LBCL), with plans to initiate the trial by the end of 2024. As part of the ANTLER Phase 1 trial, positive dose expansion results are expected to be shared in Q2 2024, along with the recommended Phase 2 dose for CB-010. Additionally, the therapy has received designations that may expedite its development.
Read more →CRBUCaribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update -- CB-010 ANTLER Phase 1 trial continues enrolling second-line r r LBCL patients in dose expansion plan to share FDA feedback
Caribou Biosciences, Inc. reported its financial results for the third quarter of 2023, highlighting progress in its clinical trials, particularly the ANTLER Phase 1 trial for CB-010 targeting second-line LBCL patients. The company holds $396.7 million in cash, anticipated to support operations until late 2025. Caribou plans to engage with the FDA regarding a potential pivotal trial for CB-010 by year's end and expects to provide initial dose expansion data in H1 2024. Additionally, the clearance of IND for its CB-012 therapy marks an important step as the company prepares to expand its clinical efforts.
Read more →CRBU▼ -6%on this news
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia -- AMpLify Phase 1 clinical trial
Caribou Biosciences has received FDA clearance for its IND application for CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy aimed at treating relapsed or refractory acute myeloid leukemia (AML). The therapy is noted for its innovative design, which includes checkpoint disruption and immune cloaking functionalities. Patient enrollment for the AMpLify Phase 1 clinical trial is expected to commence by mid-2024. The development of CB-012 addresses the pressing need for more effective treatments in a patient population with limited options.
Read more →CRBUCaribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update -- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients plan to share FDA feedback by YE 2023 and report in
Caribou Biosciences has reported its second quarter financial results and provided updates on its clinical trials. Notable advancements include the ongoing dose expansion of the CB-010 trial in second-line LBCL patients and the continued enrollment in the CaMMouflage trial for CB-011. Caribou received significant funding, including a $25 million investment from Pfizer and $134.6 million from a public offering, expected to support operations through 2025. Despite these positives, the company incurred a net loss during the quarter and experienced a slight decrease in licensing revenue.
Read more →CRBUCaribou Biosciences Announces Proposed Public Offering of Common Stock BERKELEY, CA
Caribou Biosciences, Inc. has announced a proposed public offering of common stock amounting to $100 million. The company plans to grant underwriters a 30-day option to purchase an additional $15 million in shares. While the offering aims to raise capital, it is subject to market conditions and does not guarantee successful completion or favorable terms. The opportunity is being managed by several prominent financial institutions.
Read more →CRBUCaribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r r B-NHL -- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autolog
Caribou Biosciences has reported encouraging clinical data from the dose escalation phase of its ANTLER Phase 1 trial for CB-010, an allogeneic CAR-T cell therapy targeting relapsed or refractory B cell non-Hodgkin lymphoma. The data showed a 94% overall response rate among 16 treated patients, with 69% achieving a complete response. The therapy was well tolerated, with no severe toxicities observed. The company is currently enrolling second-line patients in the dose expansion phase and anticipates sharing further data in the first half of 2024.
Read more →CRBU▲ +45.6%on this news· ran to +88% by day 3
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer -- Pfizer purchases $25 million of Caribou common shares -- -- Sriram Krishnaswami, PhD, vice president and development head, multiple myeloma, Pfiz
Caribou Biosciences announced a significant $25 million equity investment from Pfizer, which purchased 4,690,431 common shares at $5.33 each. In connection with the investment, Dr. Sriram Krishnaswami from Pfizer has joined Caribou's Scientific Advisory Board. The funds will support Caribou's advancements in their CAR-T cell therapy programs, specifically for multiple myeloma and B-cell non-Hodgkin lymphoma. The collaboration signifies a noteworthy endorsement of Caribou's innovative genome-editing technology and therapeutic potential.
Read more →CRBUCaribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update -- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion plan to report dose escalation data in H2
Caribou Biosciences reported financial results for Q1 2023, revealing a net loss of $28.0 million while progressing its clinical trials. The ongoing ANTLER Phase 1 trial for CB-010 is entering a dose expansion phase, while CB-011 has received Fast Track designation from the FDA. CB-012 is also moving forward with plans for an IND submission in the second half of 2023. The company has a strong cash position, ensuring operational funding through 2025.
Read more →CRBUCaribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma -- CaMMouflage Phase 1 trial for CB-011 enrolling patients with r r
Caribou Biosciences has received Fast Track designation from the FDA for its allogeneic CAR-T cell therapy, CB-011, aimed at treating relapsed or refractory multiple myeloma. This designation will facilitate efficient communication with the FDA as the company progresses with its clinical development. The CaMMouflage Phase 1 trial is currently enrolling patients, having recently dosed its first participant. CB-011 utilizes a novel immune cloaking strategy to enhance antitumor activity, making it the first therapy of its kind in clinical trials.
Read more →CRBU▲ +9.3%on this news
Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients -- CB-010 is the first allogeneic CAR-T cell therapy, to Caribou's knowledge, to be evaluated clinically in
Caribou Biosciences has announced the initiation of the dose expansion portion of its CB-010 ANTLER Phase 1 trial, targeting second-line large B cell lymphoma (LBCL) patients. CB-010, the first allogeneic CAR-T cell therapy being evaluated in this setting, aims to provide more accessible treatment options for patients. The trial has shown positive early results in dose escalation, with no dose-limiting toxicities noted and a promising safety profile. Caribou plans to evaluate various doses to determine the recommended Phase 2 dose and expects to present safety and efficacy data updates in the second half of 2023.
Read more →CRBUCaribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma -- CB-011 is desig
Caribou Biosciences has initiated the CaMMouflage Phase 1 trial for its allogeneic CAR-T cell therapy, CB-011, aimed at treating relapsed or refractory multiple myeloma. The trial's first patient has been dosed with CB-011, which is designed to improve antitumor activity by cloaking the CAR-T cells from immune rejection. This marks a significant step in Caribou's clinical development, showcasing their innovative immune cloaking technology. The trial aims to evaluate the safety and efficacy of CB-011 as a new treatment option for patients who have exhausted other therapies.
Read more →CRBU▼ -6.1%on this news
Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update -- CB-010 ANTLER Phase 1 trial in r r B-NHL ongoing with update planned for H2 2023 -- -- CB-011 CaMMouflage Ph
Caribou Biosciences reported its fourth quarter and full year 2022 financial results, highlighting advancements in its clinical pipeline. The company disclosed that its CB-010 Phase 1 trial showed promising results in treating relapsed or refractory B cell non-Hodgkin lymphoma, with all patients in the first cohort achieving complete responses. Additionally, Caribou has initiated IND-enabling studies for CB-012 and activated clinical sites for CB-011 to support the ongoing CaMMouflage trial. The company currently holds $317 million in cash, sufficient to fund operations into 2025.
Read more →CRBU▼ -9%on this news
Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress -- Long-term durability observed for CB-010 allogeneic cell therapy at dose level 1 in ANTLER trial for r r B-NHL -- -- ANTLER trial enrolling patients at
Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress -- Long-term durability observed for CB-010 allogeneic cell therapy at dose level 1 in ANTLER trial for r r B-NHL -- -- ANTLER trial enrolling patients at dose level 3 -- BERKELEY, CA, December 12, 2022 - Caribo
Read more →CRBUCaribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy -- RMAT and Fast Track designations follow CB-
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy -- RMAT and Fast Track designations follow CB-010's durable complete responses at dose level 1 in the AN
Read more →CRBUCaribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma -- CaMMouflage Phase 1 clinical trial to
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma -- CaMMouflage Phase 1 clinical trial to initiate patient enrollment at dose level 1 in early 2023 -
Read more →CRBUCaribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update -- CB-010 ANTLER Phase 1 trial in r r B-NHL advancing additional data from cohort 1 expected by YE 2022 -- -- CB-011 IND appli
Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update -- CB-010 ANTLER Phase 1 trial in r r B-NHL advancing additional data from cohort 1 expected by YE 2022 -- -- CB-011 IND application for r r MM submitted to FDA in Q4 2022 -- -- Stron
Read more →CRBUCaribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting BERKELEY, CA
Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting BERKELEY, CA, November 3, 2022 - Caribou Biosciences, Inc. (Nasdaq CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today ann
Read more →CRBUCaribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, Myeloma Congress 2022 -- Ongoing complete response at 15 months reported in first
Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, Myeloma Congress 2022 -- Ongoing complete response at 15 months reported in first patient treated with CB-010 -- BERKELEY, CA, October 18, 2
Read more →CRBUCaribou Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update -- 6-month CR in 3 of 6 patients across cohort 1 of the CB-010 ANTLER Phase 1 clinical trial -- -- Additional cohort 1 data e
Caribou Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update -- 6-month CR in 3 of 6 patients across cohort 1 of the CB-010 ANTLER Phase 1 clinical trial -- -- Additional cohort 1 data expected by YE 2022; enrolling patients in cohort 2 of ANT
Read more →CRBU▼ -20.4%on this news· ran to -42% by day 1
x201c;Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Pr
Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress -- 100% CR rate (6 of 6 patients), with 40% CR rate (2 of 5 patients) at 6 months, achieved as be
Read more →CRBUcurrent and future research and development programs, preclinical studies, and clinical trials; and the risk that initial or interim clinical trial data will not ultimately be predictive of the safety and efficacy of Car
Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022 -- Poster presentation at the European Hematology Association (EHA) 2022 Congress to take place on Friday, June 10 and include additional da
Read more →CRBU▲ +22.2%on this news· ran to +46% by day 3
Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy -- 100% ORR (5 of 5 patients) and 80% CR (4 of 5 patients) achieved following 1 dose at the initial dose level in pat
Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy -- 100% ORR (5 of 5 patients) and 80% CR (4 of 5 patients) achieved following 1 dose at the initial dose level in patients with aggressive r/r B-NHL -- -- CB-010 is the 1st a
Read more →CRBU▼ -9.1%on this news· ran to +34% by day 3shared move
Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors -- Mr. Johnson brings 30 years of commercial experience to Caribou as company's pipeline of genome-edited cell therapies advances -- BE
Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors -- Mr. Johnson brings 30 years of commercial experience to Caribou as company's pipeline of genome-edited cell therapies advances -- BERKELEY, CA, May 11, 2022 (GLOBE NEWSWIRE) Caribou Bioscie
Read more →CRBU▼ -9%on this newsshared move
Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates - Initial ANTLER Phase 1 clinical data scheduled to be shared at the E uropean Hematology Association (EHA) 2022 Hybrid Congr
Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates - Initial ANTLER Phase 1 clinical data scheduled to be shared at the European Hematology Association (EHA) 2022 Hybrid Congress for CB-010, the Company's lead allogeneic cell therapy
Read more →CRBUenhanced persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of patients with hematologic malignancies and solid tumors. Follow us @CaribouBio and visit www.car
Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress --Abstract accepted for initial clinical data from the ANTLER Phase 1 trial of CB-010, Caribou's lead allogeneic cell therapy for patients with r
Read more →CRBU▼ -6.3%on this news
Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update -- Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its
Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update -- Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its lead allogeneic cell therapy candidate for patients with r/
Read more →CRBU▼ -6.4%on this news
Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer Dr. Rizvi brings significant experience in oncology cell therapy development BERKELEY, CA
Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer Dr. Rizvi brings significant experience in oncology cell therapy development BERKELEY, CA, January 18, 2022 (GLOBE NEWSWIRE) Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-
Read more →CRBUCaribou Biosciences Provides Business Update and Reports Third Quarter 2021 Financial Results On track to achieve key milestones, including plan to disclose initial clinical data in 2022 for lead product candidate CB-010
Caribou Biosciences Provides Business Update and Reports Third Quarter 2021 Financial Results On track to achieve key milestones, including plan to disclose initial clinical data in 2022 for lead product candidate CB-010 Expanded leadership with appointments of Ran Zheng and D
Read more →CRBUCaribou Biosciences Appoints Dara Richardson-Heron, M.D., to its Board of Directors and Ruhi Khan as Chief Business Officer BERKELEY, CA
Caribou Biosciences Appoints Dara Richardson-Heron, M.D., to its Board of Directors and Ruhi Khan as Chief Business Officer BERKELEY, CA, November 8, 2021 (GLOBE NEWSWIRE) Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical
Read more →CRBUCaribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors BERKELEY, CA –
Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors BERKELEY, CA September 29, 2021 Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today it has appointed Ra
Read more →CRBU▲ +5.6%on this news
Caribou Biosciences Provides Business Update and Reports Second Quarter 2021 Financial Results Completed upsized initial public offering of common stock, raising $349.6 million in gross proceeds including full exercise o
Caribou Biosciences Provides Business Update and Reports Second Quarter 2021 Financial Results Completed upsized initial public offering of common stock, raising $349.6 million in gross proceeds including full exercise of underwriters' option to purchase additional shares ANTLE
Read more →CRBUCaribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors BERKELEY, CA –
Caribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors BERKELEY, CA August 25, 2021 Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has appointed Nancy Whiting, P
Read more →Competitive Position
How CRBU ranks across every disease it competes inCompetitive Position is a premium feature
See how CRBU ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial